Helen Ashwin

Helen Ashwin

Auto-generated profile, based on publicly available information

Helen Ashwin

York Biomedical Research Institute, Hull York Medical School, University of York, York, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2016 in Eurosurveillance
Verified
Journal Article
Open access
KDKerrie A Davies
Kerrie A Davies
HAHelen Ashwin
Helen Ashwin
Christopher LongshawChristopher Longshaw
Christopher Longshaw
DBDavid A Burns
David A Burns
GDGeorgina L Davis
Georgina L Davis
OGon behalf of the EUCLID study group
on behalf of the EUCLID study group
Clostridium difficile infection (CDI) is the major cause of infective diarrhoea in healthcare environments. As part of the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), the largest C. difficile epidemiological study of its type, PCR ribotype distribution of C. difficile isolates in Europe was investigated. PCR ribotyping was performed on 1,196 C. difficile isolates from diarrhoeal samples sent to the European coordinating laboratory in 2012–13 and 2013 (from two sampling days) by 482 participating hospitals from 19 European countries. A total of 125 ribotypes were identified, of which ribotypes 027 (19%, n =222), 001/072 (11%, n = 134) and 014/020 (10%, n = 119) were the most prevalent. Distinct regional patterns of ribotype distribution were noted. Of 596 isolates from patients with toxin-positive stools (CDI cases), ribotype 027 accounted for 22% (32/144) of infections in cases aged from 18 to less than 65 years, but the prevalence decreased in those aged ≥ 65 years (14% (59/412)) and further decreased in those aged ≥ 81 years (9% (18/195)). The prevalence of ribotype 027 and 176, but not other epidemic strains, was inversely proportional to overall ribotype diversity (R2 = 0.717). This study highlights an increased diversity of C. difficile ribotypes across Europe compared with previous studies, with considerable intercountry variation in ribotype distribution. Continuous surveillance programmes are necessary to monitor the changing epidemiology of C. difficile.

1 January 2005 in Analytica Chimica Acta
Verified
Journal Article
Closed access
JFJulie Ferguson
Julie Ferguson
ABAndrew Baxter
Andrew Baxter
PYPaul Young
Paul Young
GKGlenn Kennedy
Glenn Kennedy
CEChris Elliott
Chris Elliott
MSMatthew Sharman
Matthew Sharman

4 March 2010 in Analytical Chemistry
Verified
Journal Article
Closed access
SSSara L. Stead
Sara L. Stead
HAHelen Ashwin
Helen Ashwin
BJBrian H. Johnston
Brian H. Johnston
ADAnne Dallas
Anne Dallas
SKSergei A. Kazakov
Sergei A. Kazakov
BKBrendan J. Keely
Brendan J. Keely

1 January 2005 in Analytica Chimica Acta
Verified
Journal Article
Closed access
HAH.M. Ashwin
H.M. Ashwin
SSS.L. Stead
S.L. Stead
JTJ.C. Taylor
J.C. Taylor
JSJ.R. Startin
J.R. Startin
SRS.F. Richmond
S.F. Richmond
MSM. Sharman
M. Sharman

2 August 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
VPVivak Parkash
Vivak Parkash
HAHelen Ashwin
Helen Ashwin
SDShoumit Dey
Shoumit Dey
JSJovana Sadlova
Jovana Sadlova
BVBarbora Vojtkova
Barbora Vojtkova
PKPaul M. Kaye
Paul M. Kaye
The leishmaniases are globally important parasitic diseases for which no human vaccines are currently available. To facilitate vaccine development, we conducted an open-label observational study to establish a controlled human infection model (CHIM) of sand fly-transmitted cutaneous leishmaniasis (CL) caused by Leishmania major. Between 24 January and 12 August 2022, we exposed 14 participants to L. major-infected Phlebotomus duboscqi. The primary objective was to demonstrate effectiveness of lesion development (take rate) and safety (absence of CL lesion at 12 months). Secondary and exploratory objectives included rate of lesion development, parasite load and analysis of local immune responses by immunohistology and spatial transcriptomics. Lesion development was terminated by therapeutic biopsy (between days 14 and 42 after bite) in ten participants with clinically compatible lesions, one of which was not confirmed by parasite detection. We estimated an overall take rate for CL development of 64% (9/14). Two of ten participants had one and one of ten participants had two lesion recurrences 4–8 months after biopsy that were treated successfully with cryotherapy. No severe or serious adverse events were recorded, but as expected, scarring due to a combination of CL and the biopsy procedure was evident. All participants were lesion free at >12-month follow-up. We provide the first comprehensive map of immune cell distribution and cytokine/chemokine expression in human CL lesions, revealing discrete immune niches. This CHIM offers opportunities for vaccine candidate selection based on human efficacy data and for a greater understanding of immune-mediated pathology. ClinicalTrials.gov identifier: NCT04512742.

1 April 2009 in Analytica Chimica Acta
Verified
Journal Article
Closed access
FHFrédérique L. van Holthoon
Frédérique L. van Holthoon
MEMartien L. Essers
Martien L. Essers
PMPatrick J. Mulder
Patrick J. Mulder
SSSara L. Stead
Sara L. Stead
MCMarianne Caldow
Marianne Caldow
MSMatthew Sharman
Matthew Sharman